|
gptkbp:instance_of
|
gptkb:Clinical_Trials
|
|
gptkbp:analysis
|
Cox proportional hazards model
|
|
gptkbp:blinded
|
yes
|
|
gptkbp:business_model
|
yes
|
|
gptkbp:clinical_trial
|
NCT02125461
|
|
gptkbp:collaborator
|
gptkb:European_Organization_for_Research_and_Treatment_of_Cancer
gptkb:National_Institutes_of_Health
gptkb:American_Society_of_Clinical_Oncology
|
|
gptkbp:collection
|
patient questionnaires
|
|
gptkbp:committee
|
yes
|
|
gptkbp:completed
|
gptkb:2019
|
|
gptkbp:criteria
|
previous immunotherapy
stage III NSCLC patients
|
|
gptkbp:duration
|
up to 12 months
|
|
gptkbp:events
|
at least 24 months
|
|
gptkbp:finale_date
|
quality of life assessment
progression-free survival at 12 months
|
|
gptkbp:focuses_on
|
gptkb:Oncology
|
|
gptkbp:follow_up_method
|
clinical visits
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
PACIFIC trial
|
|
gptkbp:investigates
|
gptkb:durvalumab
gptkb:Dr._Scott_J._Antonia
|
|
gptkbp:investigational_site
|
hospitals worldwide
|
|
gptkbp:is_studied_in
|
multicenter, randomized, double-blind
|
|
gptkbp:is_tested_for
|
gptkb:III
|
|
gptkbp:location
|
multiple countries
|
|
gptkbp:marketed_as
|
gptkb:Imfinzi
|
|
gptkbp:members
|
placebo group
|
|
gptkbp:notable_work
|
improved overall survival
improved progression-free survival
|
|
gptkbp:participants
|
overall survival
progression-free survival
|
|
gptkbp:patient_population
|
adults
|
|
gptkbp:provides_guidance_on
|
yes
|
|
gptkbp:publication_year
|
gptkb:2018
|
|
gptkbp:regulatory_compliance
|
yes
|
|
gptkbp:related_products
|
gptkb:durvalumab
|
|
gptkbp:result
|
gptkb:The_New_England_Journal_of_Medicine
|
|
gptkbp:sampled_in
|
yes
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
rash
pneumonitis
|
|
gptkbp:sponsored_by
|
gptkb:Astra_Zeneca
|
|
gptkbp:started_in
|
gptkb:2015
|
|
gptkbp:student_enrollment
|
over 700 patients
|
|
gptkbp:study_status
|
completed
|
|
gptkbp:target_audience
|
patients with unresectable stage III NSCLC
|
|
gptkbp:treatment_comparison
|
durvalumab vs placebo
|
|
gptkbp:year
|
gptkb:2017
|
|
gptkbp:bfsParent
|
gptkb:Imfinzi
|
|
gptkbp:bfsLayer
|
5
|